Dr. Hoenle AG (HNL) AI Stock Analysis

Top Page

Dr. Hoenle AG

(XETRA:HNL)

Select Model

Rating:49Neutral

Price Target:EUR 7.00▼(-5.15% Downside)

Action:reiterated

Date:08/20/26

The score is held back primarily by weak profitability (very low gross margin and negative net income) despite strong TTM revenue growth and improved positive free cash flow. Technicals are also unfavorable with price below key moving averages and a negative MACD, while valuation is constrained by a negative P/E that reflects continuing losses.

Positive Factors

Revenue reboundThe sharp TTM revenue rebound indicates renewed demand for Hönle’s industrial UV and LED solutions and provides a stronger base for operating leverage. If sales momentum persists, the enlarged revenue base could support better utilization, product investment, and eventual margin recovery.

Negative Factors

Severe margin pressureThe collapse in gross margin shows that the strong sales rebound has not yet translated into attractive economics. Persistently negative net income limits reinvestment capacity and leaves the business dependent on a successful margin recovery before growth can produce durable shareholder returns.

Dr. Hoenle AG (HNL) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 41.12M
Dividend Yield: ―
Average Volume (3M): 2,392
Price to Earnings (P/E): -15.5
Beta (1Y): 0.81
Revenue Growth: -3.71%
EPS Growth: 78.57%
Country: Germany
Employees: 553
Sector: General
Sector Strength: 55
Industry: Electrical Equipment & Parts

Dr. Hoenle AG Business Overview & Revenue Model

Company Description

Dr. Hönle AG is a global provider specializing in industrial ultraviolet (UV) technologies and related systems, with operations spanning Germany and international markets. The company organizes its business into three main segments: Adhesives, Equipm...

How the Company Makes Money

Dr. Hönle AG primarily makes money by selling industrial UV/LED equipment and related products and services used in customers’ manufacturing and processing lines. Key revenue streams include: (1) Sales of UV/LED systems and components: revenue from d...

Dr. Hoenle AG Financial Statement Overview

Summary

Revenue rebounded sharply in TTM (~+116%) and cash flow is positive (TTM operating cash flow ~€6.3m; free cash flow ~€4.8m), but profitability remains the main drag: gross margin collapsed to ~1% and net income is still negative (~-3% margin). Leverage appears manageable (~0.6x debt/equity), yet persistently negative ROE signals the turnaround is not complete.

Income Statement

38Negative

Balance Sheet

56Neutral

Cash Flow

62Positive

Financial statement breakdown
Breakdown	TTM	Sep 2025	Sep 2024	Sep 2023	Sep 2022	Sep 2021
Income Statement
Total Revenue	92.90M	93.68M	98.73M	106.34M	116.09M	115.17M
Gross Profit	1.27M	12.47M	60.07M	53.35M	69.28M	69.34M
EBITDA	7.09M	6.00M	3.02M	779.00K	20.41M	14.02M
Net Income	-2.91M	-3.17M	-13.28M	-11.01M	-13.36M	-4.82M
Balance Sheet
Total Assets	142.67M	145.52M	155.38M	176.16M	195.46M	202.91M
Cash, Cash Equivalents and Short-Term Investments	7.23M	7.75M	7.51M	9.32M	7.13M	12.07M
Total Debt	46.62M	48.25M	53.24M	56.89M	59.53M	53.64M
Total Liabilities	66.55M	68.48M	75.70M	80.02M	88.22M	91.78M
Stockholders Equity	75.92M	76.87M	79.42M	95.82M	106.88M	110.72M
Cash Flow
Free Cash Flow	4.81M	3.17M	3.44M	209.00K	-11.71M	-15.96M
Operating Cash Flow	6.27M	5.06M	5.53M	3.14M	-7.41M	1.13M
Investing Cash Flow	780.00K	1.49M	-2.37M	2.65M	-1.69M	-24.50M
Financing Cash Flow	-5.66M	-6.44M	-4.90M	-3.42M	3.73M	1.25M

Dr. Hoenle AG Technical Analysis

Technical Analysis SentimentNegative

Last Price7.38

Price Trends

50DMA7.58Negative

100DMA7.98Negative

200DMA8.60Negative

Market Momentum

MACD-0.08Negative

RSI46.40Neutral

STOCH49.38Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HNL, the sentiment is Negative. The current price of 7.38 is below the 20-day moving average (MA) of 7.41, below the 50-day MA of 7.58, and below the 200-day MA of 8.60, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 46.40 is Neutral, neither overbought nor oversold. The STOCH value of 49.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:HNL.

Dr. Hoenle AG Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

DE:HNL against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
DE:SMHN	55Neutral	EUR 973.94M	35.14	8.73%	0.08%	-15.45%	-51.36%
DE:MXHN	51Neutral	EUR 102.70M	-48.63	-1.09%	―	-8.60%	-107.57%
DE:HNL	49Neutral	EUR 44.74M	-15.47	-3.82%	―	-3.71%	78.57%
DE:SNG	48Neutral	EUR 102.75M	-8.85	18.15%	―	-6.77%	-47.94%
DE:LPK	46Neutral	EUR 251.09M	-11.02	-33.16%	―	-26.24%	-2180.10%

* General Sector Average

Performance Comparison

DE:HNL and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:HNL	Dr. Hoenle AG	7.38	-0.08	-1.07%
DE:LPK	LPKF Laser & Electronics	10.25	3.47	51.20%
DE:M5Z	Manz AG	0.01	-0.05	-83.61%
DE:MXHN	MAX Automation	2.49	-3.29	-56.91%
DE:SNG	Singulus Technologies	11.55	10.11	699.86%
DE:SMHN	Suss Microtec Se	50.95	22.90	81.65%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 20, 2026

Dr. Hoenle AG AI Stock Analysis